528 related articles for article (PubMed ID: 24725691)
21. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
22. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Zohren F; Czibere A; Bruns I; Fenk R; Schroeder T; Gräf T; Haas R; Kobbe G
Bone Marrow Transplant; 2009 Dec; 44(12):785-92. PubMed ID: 19430496
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
26. Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens.
Shinde A; Yang D; Frankel P; Liu A; Han C; Del Vecchio B; Schultheiss T; Cheng J; Li R; Kim D; Radany EH; Hui S; Somlo G; Rosenthal J; Stein A; Forman S; Wong JYC
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1025-1033. PubMed ID: 31421151
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
28. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation.
Wong JY; Liu A; Schultheiss T; Popplewell L; Stein A; Rosenthal J; Essensten M; Forman S; Somlo G
Biol Blood Marrow Transplant; 2006 Mar; 12(3):306-15. PubMed ID: 16503500
[TBL] [Abstract][Full Text] [Related]
29. Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant.
Corvò R; Zeverino M; Vagge S; Agostinelli S; Barra S; Taccini G; Van Lint MT; Frassoni F; Bacigalupo A
Radiother Oncol; 2011 Mar; 98(3):382-6. PubMed ID: 21339008
[TBL] [Abstract][Full Text] [Related]
30. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
Belkacémi Y; Ozsahin M; Rio B; Laporte JP; Leblond V; Pène F; Laugier A
Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
[TBL] [Abstract][Full Text] [Related]
31. The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.
Hamidieh A; Kargar M; Jahani M; Alimoghaddam K; Bahar B; Mousavi SA; Iravani M; Jalali A; Jalili M; Ghavamzadeh A
J Pediatr Hematol Oncol; 2012 Mar; 34(2):101-7. PubMed ID: 22367385
[TBL] [Abstract][Full Text] [Related]
32. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of myeloablative conditioning with 3-day total marrow and lymphoid irradiation for leukemia.
Ogawa H; Konishi T; Najima Y; Kito S; Hashimoto S; Kato C; Sakai S; Kanbara Y; Atsuta Y; Konuma R; Wada A; Murakami D; Nakasima S; Uchibori Y; Onai D; Hamamura A; Nishijima A; Shingai N; Toya T; Shimizu H; Kobayashi T; Ohashi K; Doki N; Murofushi KN
Cancer Sci; 2023 Feb; 114(2):596-605. PubMed ID: 36221800
[TBL] [Abstract][Full Text] [Related]
34. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
36. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
37. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation.
Simpson DR; Nevill TJ; Shepherd JD; Fung HC; Horsman DE; Nantel SH; Vickars LM; Sutherland HJ; Toze CL; Hogge DE; Klingemann HG; Naiman SC; Barnett MJ
Bone Marrow Transplant; 1998 Aug; 22(3):259-64. PubMed ID: 9720739
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.
Czyz A; Labopin M; Giebel S; Socié G; Apperley J; Volin L; Reményi P; Yakoub-Agha I; Orchard K; Michallet M; Stuhler G; Chaganti S; Murray M; Aljurf M; Bloor A; Passweg J; Finke J; Mohty M; Nagler A
Am J Hematol; 2018 Jun; 93(6):778-785. PubMed ID: 29574915
[TBL] [Abstract][Full Text] [Related]
39. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
